Home / Cybersecurity / The Company Working to Build a Cancer Drug With AI Is Opening a Lab in Israel

Cybersecurity

The Company Working to Build a Cancer Drug With AI Is Opening a Lab in Israel

15 novembre 2021

DeepCure uses artificial intelligence to scan a molecule database to develop effective, safe medication while cutting down the lengthy traditional process

The U.S. startup company DeepCure, which works to develop medications with the help of artificial intelligence, said this week that it will be opening a lab and offices in Israel for the first time.

DeepCure is part of an emerging wave of companies seeking to improve and accelerate the drug-development process with tools like machine learning and AI. It was formed in 2018 by CEO Kfir Schreiber, alongside Joseph Jacobson and Thrasyvoulos (Thras) Karydis, who are today chief science and chief technology officer, respectively. The three met as students at the Massachusetts Institute of Technology.

Mots-clés : cybersécurité, sécurité informatique, protection des données, menaces cybernétiques, veille cyber, analyse de vulnérabilités, sécurité des réseaux, cyberattaques, conformité RGPD, NIS2, DORA, PCIDSS, DEVSECOPS, eSANTE, intelligence artificielle, IA en cybersécurité, apprentissage automatique, deep learning, algorithmes de sécurité, détection des anomalies, systèmes intelligents, automatisation de la sécurité, IA pour la prévention des cyberattaques.